J&J reaches $6m settlement over counterfeit surgical tools

Johnson & Johnson (J&J) has settled its case against Advanced Inventory Management (AIM), trading as eSutures, which it accused of distributing counterfeit and contaminated surgical tools.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

Report: Market for anti-counterfeit drugs packaging to hit $191bn by 2030

24 January 2023 New study examines industry by product, application and region | China, Germany and India predicted to see the largest growth.

Americas

Surgical device maker hit with $10m damages in stapler patent dispute

20 October 2022 Lawsuit centred on methods for stapling tissue during surgery | Delaware federal jury found in favour of Rex Medical.

Americas

Federal Circuit backs PTAB in Johnson & Johnson patent appeal

4 January 2017 The US Court of Appeals for the Federal Circuit has affirmed a Patent Trial and Appeal Board decision that said patent claims owned by Ethicon, a subsidiary of Johnson & Johnson (J&J), are invalid.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

J&J reaches $6m settlement over counterfeit surgical tools

More on this story

Editor's picks

Editor's picks

More features